Verona Pharma plc (F:I9SA) — Market Cap & Net Worth
Market Cap & Net Worth: Verona Pharma plc (I9SA)
Verona Pharma plc (F:I9SA) has a market capitalization of $9.07 Billion (€7.76 Billion) as of August 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #2381 globally and #490 in its home market, demonstrating a 0.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verona Pharma plc's stock price €90.20 by its total outstanding shares 85991311 (85.99 Million). See reinvestment intensity of Verona Pharma plc to understand how much of operating cash flow is reinvested back into capital assets.
Verona Pharma plc Market Cap History: 2018 to 2025
Verona Pharma plc's market capitalization history from 2018 to 2025. Data shows growth from $761.54 Million to $9.07 Billion (36.52% CAGR).
Verona Pharma plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verona Pharma plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
107.95x
Verona Pharma plc's market cap is 107.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $598.17 Million | $40.00 Million | -$55.57 Million | 14.95x | N/A |
| 2022 | $2.37 Billion | $458.00K | -$68.70 Million | 5180.30x | N/A |
| 2024 | $4.56 Billion | $42.28 Million | -$173.42 Million | 107.95x | N/A |
Competitor Companies of I9SA by Market Capitalization
Companies near Verona Pharma plc in the global market cap rankings as of August 1, 2026.
Key companies related to Verona Pharma plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Verona Pharma plc Historical Marketcap From 2018 to 2025
Between 2018 and today, Verona Pharma plc's market cap moved from $761.54 Million to $ 9.07 Billion, with a yearly change of 36.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €9.07 Billion | +98.68% |
| 2024 | €4.56 Billion | +141.49% |
| 2023 | €1.89 Billion | -20.34% |
| 2022 | €2.37 Billion | +296.64% |
| 2021 | €598.17 Million | +12.46% |
| 2020 | €531.92 Million | -4.67% |
| 2019 | €557.96 Million | -26.73% |
| 2018 | €761.54 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Verona Pharma plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.07 Billion USD |
| MoneyControl | $9.07 Billion USD |
| MarketWatch | $9.07 Billion USD |
| marketcap.company | $9.07 Billion USD |
| Reuters | $9.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more